Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase II Clinical Study to Evaluate the Efficacy and Safety of ALT001 in Patients With Ischemic Stroke in the Sequelae Stage

NCT07841496 is registered in ClinicalTrials.gov with Darwin Origin (Hubei) Biopharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07841496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07841496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase II Clinical Study to Evaluate the Efficacy and Safety of ALT001 in Patients With Ischemic Stroke in the Sequelae Stage
Lead sponsor
Darwin Origin (Hubei) Biopharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 21, 2026
Completion date
October 31, 2027
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ischemic stroke in the sequelae stage